Poly(D,L-lactide-co-glycolide) nanoparticles significantly enhance the immunoprotective efficacy of Ascaridia galli excretory-secretory antigens

聚(D,L-乳酸-共-乙醇酸)纳米颗粒显著增强鸡蛔虫排泄分泌抗原的免疫保护功效

阅读:2

Abstract

Ascaridia galli infection causes significant economic losses in poultry, with no available vaccine. This study aimed to develop and evaluate a novel nanovaccine by encapsulating A. galli excretory-secretory antigens (ESAs) in poly(lactic-co-glycolic acid) (PLGA) and chitosan (CS) nanoparticles (NPs), comparing their efficacy to antigens delivered with Freund's adjuvant (FA). One-day-old chicks were randomly allocated into five groups. Three treatment groups were immunized intramuscularly on days 7 and 14 with 200 μg of A. galli ESAs delivered via PLGA NPs, CS NPs, or FA. An infected control group and an uninfected blank control group were also included. All groups except the blank control were challenged with 500 infective A. galli larvae on day 21. On day 77, chickens were euthanized for assessment of worm burden, growth performance, antibody responses (systemic and mucosal), and cytokine profiles. Immunization with ESAs-PLGA NPs induced the most significant reduction in total worm burden (34.38%), which was particularly effective against male worms. This group, along with the ESAs-CS NPs group, also showed a significant improvement in average daily weight gain compared to the infected control. Serologically, both NP groups elicited significantly higher and more sustained levels of serum total IgG and ESAs-specific IgG than the FA group. Crucially, only the ESAs-PLGA NPs significantly enhanced IgG levels in the jejunal mucosa. Furthermore, the ESAs-PLGA NP vaccine consistently promoted the strongest Th2-type immune response, characterized by the highest secretion of IL-4 and IL-13. A. galli ESAs are effective vaccine antigens that confer protection by stimulating IgG antibodies and a Th2-skewed immune response. Encapsulation of ESAs in PLGA NPs significantly enhances this immunoprotective efficacy, superior to both CS NPs and traditional FA, by potentiating systemic and mucosal humoral immunity and amplifying Th2-cell responses. The ESAs-PLGA NP formulation represents a promising vaccine candidate for controlling A. galli in poultry.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。